- Home
- SNT vs ONCY Comparison
SNT vs ONCY Comparison
Compare SNT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ONCY
- Stock Information
- Founded
- SNT 1965
- ONCY 1998
- Country
- SNT Canada
- ONCY Canada
- Employees
- SNT N/A
- ONCY N/A
- Industry
- SNT Telecommunications Equipment
- ONCY Pharmaceuticals and Biotechnology
- Sector
- SNT Telecommunications
- ONCY Health Care
- Exchange
- SNT Nasdaq
- ONCY Nasdaq
- Market Cap
- SNT 95.2M
- ONCY 89.7M
- IPO Year
- SNT 1993
- ONCY 1999
- Fundamental
- Price
- SNT $4.25
- ONCY $1.35
- Analyst Decision
- SNT
- ONCY Strong Buy
- Analyst Count
- SNT 0
- ONCY 5
- Target Price
- SNT N/A
- ONCY $5.00
- AVG Volume (30 Days)
- SNT 56.6K
- ONCY 1.2M
- Earning Date
- SNT 11-11-2025
- ONCY 11-11-2025
- Dividend Yield
- SNT N/A
- ONCY N/A
- EPS Growth
- SNT N/A
- ONCY N/A
- EPS
- SNT 0.22
- ONCY N/A
- Revenue
- SNT $38,038,000.00
- ONCY N/A
- Revenue This Year
- SNT N/A
- ONCY N/A
- Revenue Next Year
- SNT N/A
- ONCY N/A
- P/E Ratio
- SNT $19.96
- ONCY N/A
- Revenue Growth
- SNT 12.79
- ONCY N/A
- 52 Week Low
- SNT $1.40
- ONCY $0.33
- 52 Week High
- SNT $5.04
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- SNT 43.70
- ONCY 64.00
- Support Level
- SNT $4.42
- ONCY $1.20
- Resistance Level
- SNT $4.74
- ONCY $1.44
- Average True Range (ATR)
- SNT 0.21
- ONCY 0.11
- MACD
- SNT -0.01
- ONCY 0.01
- Stochastic Oscillator
- SNT 5.77
- ONCY 79.07
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.